Selank

Seven-residue peptide built on the tuftsin backbone, characterized in neuropeptide receptor research models. For in-vitro research only.

• In a neuroblastoma IMR-32 culture screened across 84 genes of the GABAergic and neurotransmission panel, the peptide alone produced no change in the measured mRNA levels, while combined exposures with GABA or with olanzapine gave different patterns. [1]
• Radioligand work on isolated brain cell plasma membranes reported the peptide acting on tritiated GABA binding as a positive allosteric modulator, and its joint action with benzodiazepines was not additive. [2]
• Applied to rat hippocampal slices the peptide raised the amplitude and discharge rate of spontaneous inhibitory postsynaptic currents in CA1 pyramidal neurons, with no significant concentration dependence across the range tested. [3]
• Thromboelastography of whole blood placed the heptapeptide among arginine containing glyproline oligopeptides that shifted clotting parameters toward hypocoagulation, and it showed the strongest shift of the three tested sequences. [4]

Compound

Selank

Purity

99.40% (HPLC)

Identity

Confirmed by MS

Appearance

White lyophilate

Presentation

10 mg

Catalog / lot

RV-0031 / RV-24-0031-1

For research use only. Not for human or veterinary use. Not a drug, food, cosmetic, or supplement.

Review the laboratory, lot identifier, and reported results in this document. Keep the lot identifier with your research records.